Current stock page

Catalysts

SMMT Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

SMMTSummit Therapeutics Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$14.15−$0.92 (−6.14%)

Latest quote

  • Momentum
    65
  • Value
    —
  • Quality
    30
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 22, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 47/100

Momentum 65/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 19.95%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 65/100AIQ Edge 8/10 Strong Relative Position
Beat rate
38%
3 of 8 reported periods
Average surprise
-120.0%
Across covered historical reports
Latest result
+7.7%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$0.28-$0.26+7.7%$111.11K—
Jul 23, 2026—-$0.27-$0.28-2.0%$113.89K—
Apr 30, 2026—-$0.33-$0.24+27.3%$54.42K—
Feb 23, 2026—-$0.10-$0.29-182.5%$56.78M—
Oct 20, 2025—-$0.18-$0.31-76.4%$76.5M—
Aug 11, 2025—-$0.09-$0.76-736.9%——
May 1, 2025—-$0.09-$0.09+3.2%——
Feb 24, 2025—-$0.08-$0.08+0.0%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
6
Hold
12-month analyst target
$31.50
+122.61% versus current price
Based on 17 analyst observations. Targets are estimates, not predictions.
Low target
$20.00
+41.34% vs latest price
Average target
$31.50
+122.61% vs latest price
High target
$41.00
+189.75% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 22, 2027

Next known earnings or reporting date.

EPS estimate-$0.34

Current analyst expectation for the upcoming report.

Revenue estimate$3.01M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score65

Where event reaction would show up first.

AIQ score47/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
17
Average target
$31.50
Target upside
122.61%
Target range
$20.00 - $41.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
1
gurufocus.com · Oct 25, 2026

Summit Therapeutics' Ivonescimab Shows Survival Benefit in Biliary Tract Cancer, SMMT Stock Reacts

On October 25, 2026, Summit Therapeutics Inc (NASDAQ: SMMT) announced positive phase 3 clinical trial results for its cancer drug ivonescimab, which significant

gurufocus.com · Oct 23, 2026

Summit Therapeutics (SMMT) Partners with Lunit to Advance AI-Driven Immuno-Oncology Research

On October 23, 2026, Summit Therapeutics Inc (NASDAQ: SMMT) announced a collaborative research agreement with Lunit to leverage Lunit SCOPE IO, an AI-based path

insidermonkey.com · Oct 2, 2026

AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up

AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies' cancer drugs.

rttnews.com · Sep 29, 2026

Summit Therapeutics Stock Rises 7% After AstraZeneca Strategic Investment

Summit Therapeutics Inc. (SMMT) is up 6.52 percent, gaining $1.01 to $16.49 on Tuesday. The move follows yesterday's announcement that AstraZeneca agreed to make a $2.

seekingalpha.com · Sep 17, 2026

Summit Therapeutics: It’s Okay Not To Have An Answer (NASDAQ:SMMT)

Summit Therapeutics is rated Hold at $17.50 due to high uncertainty and insufficient conviction to take a position. Read more on SMMT stock here.

Open full news and sentiment

SMMT Catalysts FAQ

What are the next catalysts for SMMT stock?

SMMT's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move SMMT stock?

Upcoming events that could move SMMT include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could SMMT's next earnings report affect the stock?

SMMT's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive SMMT stock higher?

SMMT could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt SMMT stock?

SMMT could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.